Ravulizumab is a potent and long-acting complement C5 inhibitor used to manage complement-mediated disorders. As a humanized IgG2/4 kappa monoclonal antibody, it binds with high affinity to complement protein C5, preventing its cleavage into pro-inflammatory fragments C5a and C5b. This blockade effectively halts the formation of the membrane attack complex (C5b-9), thereby reducing terminal complement-mediated inflammation, cell activation, and lysis. Ravulizumab is structurally derived from eculizumab, with enhanced pharmacokinetics that enable less frequent dosing.
In clinical and research settings, ravulizumab is a key therapeutic biomarker for monitoring and managing conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and other disorders driven by complement dysregulation, including myasthenia gravis. Its ability to suppress intravascular hemolysis and thrombotic microangiopathy underscores its utility in modulating excessive immune responses and preventing long-term organ damage.
From a therapeutic drug monitoring (TDM) perspective, ravulizumab levels may be assessed to ensure consistent suppression of the complement pathway, optimize patient-specific dosage regimens, and reduce the risk of relapse or breakthrough hemolysis. Monitoring anti-drug antibodies (ADAs) and neutralizing antibody formation also supports improved drug efficacy, compliance, and reduced adverse immune reactions.
This product is manufactured in Turkey by Matriks Biotek.